Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lutetium Lu 177 Anti-PD-L1 Nanobody RAD204

Radiopharmaceutical · Kills target cells, directed at programmed cell death 1 ligand 1 (CD274) · developed by Radiopharm Theranostics

Early Phase 1 Most advanced trial
RADX Developer
1 Registered trials

What is Lutetium Lu 177 Anti-PD-L1 Nanobody RAD204?

Lutetium Lu 177 anti-PD-L1 nanobody RAD204 is a radioimmunoconjugate in which a nanobody binds PD-L1 on tumor cells and delivers beta radiation from lutetium-177 to those cells. It is also intended for imaging PD-L1 expression by SPECT/CT. It is being studied in non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, melanoma, head and neck squamous cell carcinoma, and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
177Lu-RAD204
Drug type
Radiopharmaceutical
Targets
programmed cell death 1 ligand 1 (CD274)
Mechanism
Kills target cells, directed at programmed cell death 1 ligand 1 (CD274)
Therapy area
Oncology
Developer
Radiopharm Theranostics, Ltd (RADX)
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06305962 Early Phase 1 PDL1 Gene Mutation Recruiting RADX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cutaneous MelanomaEndometrial CancerHNSCCMmr DeficiencyMSI-HighNon Small Cell Lung CancerPDL1 Gene MutationSmall Cell Lung Cancer ( SCLC )TNBC, Triple Negative Breast Cancer

Other drugs acting on CD274

More from Radiopharm Theranostics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.

Follow RADX, the company behind Lutetium Lu 177 Anti-PD-L1 Nanobody RAD204

See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RADX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.